UCB SA (FRA:UNC0)

Germany flag Germany · Delayed Price · Currency is EUR
120.00
-2.00 (-1.64%)
At close: Dec 4, 2025
31.15%
Market Cap 45.58B
Revenue (ttm) 6.85B
Net Income (ttm) 1.33B
Shares Out n/a
EPS (ttm) 6.87
PE Ratio 34.22
Forward PE 26.78
Dividend 0.43 (0.36%)
Ex-Dividend Date Apr 28, 2025
Volume n/a
Average Volume n/a
Open 120.00
Previous Close 122.00
Day's Range 120.00 - 120.00
52-Week Range 66.50 - 129.00
Beta n/a
RSI 57.99
Earnings Date Feb 26, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spra... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1925
Employees 9,378
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol UNC0
Full Company Profile

Financial Performance

In 2024, UCB SA's revenue was 6.15 billion, an increase of 18.72% compared to the previous year's 5.18 billion. Earnings were 1.07 billion, an increase of 210.50%.

Financial Statements

News

There is no news available yet.